Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the full year ended December 31, 2017. The Company also summarized recent program updates and reiterated full-year 2018 revenue and net cash spend guidance. As quoted in the press release: John F. …

As quoted in the press release:

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “Throughout 2017 we continued to build a leading global rare disease biotech company. In the early part of 2018 we have made significant progress to further advance our vision to maximize the impact of our medicines for people living with rare metabolic diseases. There is tremendous momentum for the launch and regulatory review processes for Galafold as we expand global access to this important oral precision medicine for Fabry disease. In addition, the longer term data from our Pompe clinical study further strengthen the potential of our new treatment paradigm for this devastating muscle disease. With these key value drivers in Fabry and Pompe, supported by a strengthened balance sheet and several pipeline opportunities, Amicus is well positioned to create significant near- and long-term value for patients and shareholders.”

Click here to read the full press release.